{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T00:39:11Z","timestamp":1790987951745,"version":"4.1.0"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2011,4,1]],"date-time":"2011-04-01T00:00:00Z","timestamp":1301616000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>This article provides information and a commentary on key trials relevant to the pathophysiology, prevention, and treatment of heart failure presented at the annual meeting of the American Heart Association held in Chicago in 2010. Unpublished reports should be considered as preliminary, since analyses may change in the final publication. In patients with mild heart failure (HF), EMPHASIS-HF showed that the addition of eplerenone to standard therapy was well tolerated and reduced both the risk of death and hospitalization. The addition of cardiac resynchronization therapy to implantable cardioverter defibrillator (ICD) therapy reduced the incidence of all-cause mortality and HF hospitalizations in patients with NYHA class II\u2013III HF compared with ICD alone in RAFT. Telemonitoring failed to improve outcome compared with a high standard of conventional care in patients with chronic HF (TIM-HF study) and a telephone-based interactive voice response system failed to improve outcome in patients recently hospitalized for HF (Tele-HF study). ASCEND-HF suggested that nesiritide was ineffective but safe in patients with acute decompensated HF. ROCKET-AF suggests that the factor-Xa inhibitor rivaroxaban may be as effective as warfarin in patients with atrial fibrillation. The PROTECT study provided more data to suggest that amino-terminal B-type natriuretic peptide guided therapy may be beneficial in patients with left ventricular systolic dysfunction.<\/jats:p>","DOI":"10.1093\/eurjhf\/hfr015","type":"journal-article","created":{"date-parts":[[2011,3,24]],"date-time":"2011-03-24T11:39:38Z","timestamp":1300966778000},"page":"460-465","source":"Crossref","is-referenced-by-count":35,"title":["Clinical Trials Update from the American Heart Association Meeting 2010: EMPHASIS-HF, RAFT, TIM-HF, Tele-HF, ASCEND-HF, ROCKET-AF, and PROTECT"],"prefix":"10.1093","volume":"13","author":[{"given":"John G.F.","family":"Cleland","sequence":"first","affiliation":[{"name":"Department of Cardiology, Hull York Medical School, Daisy Building, University of Hull, Castle Hill Hospital , Cottingham, Kingston-upon-Hull, HU16 5JQ ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison P.","family":"Coletta","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hull York Medical School, Daisy Building, University of Hull, Castle Hill Hospital , Cottingham, Kingston-upon-Hull, HU16 5JQ ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laszlo","family":"Buga","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hull York Medical School, Daisy Building, University of Hull, Castle Hill Hospital , Cottingham, Kingston-upon-Hull, HU16 5JQ ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renjith","family":"Antony","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hull York Medical School, Daisy Building, University of Hull, Castle Hill Hospital , Cottingham, Kingston-upon-Hull, HU16 5JQ ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierpaolo","family":"Pellicori","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hull York Medical School, Daisy Building, University of Hull, Castle Hill Hospital , Cottingham, Kingston-upon-Hull, HU16 5JQ ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Freemantle","sequence":"additional","affiliation":[{"name":"School of Health and Population Sciences, University of Birmingham , Edgbaston, Birmingham, B15 2TT ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew L.","family":"Clark","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hull York Medical School, Daisy Building, University of Hull, Castle Hill Hospital , Cottingham, Kingston-upon-Hull, HU16 5JQ ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2014,2,18]]},"reference":[{"key":"2026020203305293900_ejhfhfr015-bib-0001","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomised Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Eng J Med"},{"key":"2026020203305293900_ejhfhfr015-bib-0002","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Eng J Med"},{"key":"2026020203305293900_ejhfhfr015-bib-0003","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.ejheart.2008.08.005","article-title":"ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008 The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM)","volume":"10","author":"Dickstein","year":"2008","journal-title":"Eur J Heart Fail"},{"key":"2026020203305293900_ejhfhfr015-bib-0004","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1093\/eurjhf\/hfn015","article-title":"Anti-remodelling effect of canrenone in patients with mild chronic heart failure (AREA IN-CHF study): final results","volume":"11","author":"Boccanelli","year":"2009","journal-title":"Eur J Heart Fail"},{"key":"2026020203305293900_ejhfhfr015-bib-0005","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1161\/CIRCHEARTFAILURE.109.906909","article-title":"Randomized double-blind multicentre placebo-controlled study evaluating the effect of aldosterone antagonism with eplerenone on ventricular remodelling in patients with mild-to-moderate heart failure and left ventricular systolic dysfunction","volume":"3","author":"Udelson","year":"2010","journal-title":"Circ Heart Fail"},{"key":"2026020203305293900_ejhfhfr015-bib-0006","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/eurjhf\/hfq049","article-title":"Rationale and design of the eplerenone in mild patients hospitalization and survival study in heart failure (EMPHASIS-HF)","volume":"12","author":"Zannad","year":"2010","journal-title":"Eur J Heart Fail"},{"key":"2026020203305293900_ejhfhfr015-bib-0007","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Eng J Med"},{"key":"2026020203305293900_ejhfhfr015-bib-0008","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.ahj.2010.04.024","article-title":"Effect of eplerenone versus spironolactone on cortisol and hemoglobin A1(c) levels in patients with chronic heart failure","volume":"160","author":"Yamaji","year":"2010","journal-title":"Am Heart J"},{"key":"2026020203305293900_ejhfhfr015-bib-0009","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1093\/eurjhf\/hfp149","article-title":"Implementation of device therapy (cardiac resynchronisation therapy and implantable cardioverter defibrillator) for patients with heart failure in Europe: changes from 2004 to 2008","volume":"11","author":"van Veldhuisen","year":"2009","journal-title":"Eur J Heart Fail"},{"key":"2026020203305293900_ejhfhfr015-bib-0010","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1056\/NEJMoa0906431","article-title":"Cardiac resynchronisation therapy for the prevention of heart failure events","volume":"361","author":"Moss","year":"2009","journal-title":"N Eng J Med"},{"key":"2026020203305293900_ejhfhfr015-bib-0011","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1009540","article-title":"Cardiac resynchronization therapy for mild to moderate heart failure","volume":"363","author":"Tang","year":"2010","journal-title":"N Eng J Med"},{"key":"2026020203305293900_ejhfhfr015-bib-0012","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.ejheart.2005.11.014","article-title":"Cardiac resynchronisation for patients with heart failure due to left ventricular systolic dysfunction\u2014a systematic review and meta-analysis","volume":"8","author":"Freemantle","year":"2006","journal-title":"Eur J Heart Fail"},{"key":"2026020203305293900_ejhfhfr015-bib-0013","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1016\/j.jacc.2008.08.027","article-title":"Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms","volume":"52","author":"Linde","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"2026020203305293900_ejhfhfr015-bib-0014","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1093\/eurheartj\/ehl099","article-title":"Longer term effects of cardiac resynchronization therapy on mortality in heart failure [the cardiac resynchronization-heart failure (CARE-HF) trial extension phase]","volume":"16","author":"Cleland","year":"2006","journal-title":"Eur Heart J"},{"key":"2026020203305293900_ejhfhfr015-bib-0015","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1136\/hrt.2007.128991","article-title":"Long-term effect of cardiac resynchronisation in patients reporting mild symptoms of heart failure: a report from the CARE-HF study","volume":"94","author":"Cleland","year":"2008","journal-title":"Heart"},{"key":"2026020203305293900_ejhfhfr015-bib-0016","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1093\/eurjhf\/hfq192","article-title":"2010 Focused update of ESC guidelines on device therapy in heart failure","volume":"12","author":"Dickstein","year":"2010","journal-title":"Eur J Heart Fail"},{"key":"2026020203305293900_ejhfhfr015-bib-0017","doi-asserted-by":"crossref","DOI":"10.1093\/eurjhf\/hfr039","article-title":"Which components of heart failure programmes are effective? A meta-analysis of the outcomes of structured telephone support or telemonitoring as the primary component of chronic heart failure management in 9,560 patients (Abridged Cochrane Review)","author":"Inglis","year":"2011","journal-title":"Eur J Heart Fail"},{"key":"2026020203305293900_ejhfhfr015-bib-0018","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1093\/eurjhf\/hfq199","article-title":"Telemedical interventional monitoring in heart failure (TIM-HF), a randomized, controlled intervention trial investigating the impact of telemedicine on mortality in ambulatory patients with heart failure: study design","volume":"12","author":"Koehler","year":"2010","journal-title":"Eur J Heart Fail"},{"key":"2026020203305293900_ejhfhfr015-bib-0019","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1056\/NEJMoa1010029","article-title":"Telemonitoring in patients with heart failure","volume":"363","author":"Chaudry","year":"2010","journal-title":"N Eng J Med"},{"key":"2026020203305293900_ejhfhfr015-bib-0020","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S0140-6736(02)09455-2","article-title":"Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial","volume":"360","author":"Follath","year":"2002","journal-title":"Lancet"},{"key":"2026020203305293900_ejhfhfr015-bib-0021","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1001\/jama.297.17.1883","article-title":"Levosimendan vs dobutamine for patients with acute decompensated heart failure the SURVIVE randomized trial","volume":"297","author":"Mebazza","year":"2007","journal-title":"JAMA"},{"key":"2026020203305293900_ejhfhfr015-bib-0022","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1001\/jama.298.17.2009","article-title":"Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials","volume":"298","author":"McMurray","year":"2007","journal-title":"JAMA"},{"key":"2026020203305293900_ejhfhfr015-bib-0023","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1093\/eurjhf\/hfp162","article-title":"Clinical trials update from the European Society of Cardiology Meeting 2009: AAA, RELY, PROTECT, ACTIVE-I, European CRT survey, German pre-SCD II registry, and MADIT-CRT","volume":"11","author":"Cleland","year":"2009","journal-title":"Eur J Heart Fail"},{"key":"2026020203305293900_ejhfhfr015-bib-0024","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Eng J Med"},{"key":"2026020203305293900_ejhfhfr015-bib-0025","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1093\/eurjhf\/hfp071","article-title":"Clinical trials update from the American College of Cardiology 2009: ADMIRE-HF, PRIMA, STICH, REVERSE, IRIS, partial ventricular support, FIX-HF-5, vagal stimulation, REVIVAL-3, pre-RELAX-AHF, ACTIVE-A, HF-ACTION, JUPITER, AURORA and OMEGA","volume":"11","author":"Cleland","year":"2009","journal-title":"Eur J Heart Fail"},{"key":"2026020203305293900_ejhfhfr015-bib-0026","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.ejheart.2008.07.014","article-title":"State of the art: using natriuretic peptide levels in clinical practice","volume":"10","author":"Maisel","year":"2008","journal-title":"Eur J Heart Fail"},{"key":"2026020203305293900_ejhfhfr015-bib-0027","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.ahj.2009.06.018","article-title":"Biomarker guided therapy in chronic heart failure: a meta-analysis of randomized controlled trials","volume":"158","author":"Felker","year":"2009","journal-title":"Am Heart J"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1093%2Feurjhf%2Fhfr015","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/13\/4\/460\/66469940\/eurjhf_13_4_460.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/13\/4\/460\/66469940\/eurjhf_13_4_460.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T08:31:02Z","timestamp":1770021062000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/13\/4\/460\/8430959"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4,1]]},"references-count":27,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2014,2,18]]},"published-print":{"date-parts":[[2011,4,1]]}},"URL":"https:\/\/doi.org\/10.1093\/eurjhf\/hfr015","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2011,4]]},"published":{"date-parts":[[2011,4,1]]}}}